Jiaping He

Years Active: 2022-2023
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Shiqi Li, Xinxin Wang, Lin Liu, Jia Liu, Jun Rao, Zhongtao Yuan, Li Gao, Yu Li, Le Luo, Gui Li, Zhimin Li, Sheng Li, Jiaping He, Lihua Zhang, Lvzhe Chen, Wenhui Huang, Ping Yin, Chunmin Li, Xiaoping Li, Youcheng Wang, Yancheng Dong, Dingsong Zhang, Qingying Zang, Yingnian Chen, Lianjun Shen, Wenling Li, Wei Cao, Xi Zhang, Sanbin Wang
CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies. Leukemia (2023)
Junfang Yang, Jiaping He, Xian Zhang, Jingjing Li, Zhenguang Wang, Yongliang Zhang, Liyuan Qiu, Qionglu Wu, Zhe Sun, Xun Ye, Wenjie Yin, Wei Cao, Lianjun Shen, Martina Sersch, Kai-Yan Liu
Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Blood cancer journal 12 (7) (2022)
Cheng Zhang, Jiaping He, Li Liu, Jishi Wang, Sanbin Wang, Ligen Liu, Jian Ge, Lei Gao, Li Gao, Peiyan Kong, Yao Liu, Jia Liu, Yu Han, Yongliang Zhang, Zhe Sun, Xun Ye, Wenjie Yin, Martina Sersch, Lianjun Shen, Wei William Cao, Xi Zhang
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia. Blood cancer journal 12 (6) (2022)

Jiaping He.css-eqlu8i{font-size:small;padding-left:4px;}